Erasca dips as ERAS-0015 Phase 1 data window tightened to mid-May 2026
Erasca shares are sliding after the company tightened the expected timing for initial Phase 1 monotherapy data for ERAS-0015 to no later than mid-May 2026. The pullback follows a sharp run-up toward a 52-week high, leaving the stock sensitive to profit-taking ahead of the catalyst.
1. What’s moving ERAS today
Erasca (ERAS) is trading lower as investors react to a newly updated timeline for its lead pan-RAS molecular glue program, ERAS-0015. The company narrowed the expected timing for the initial Phase 1 monotherapy data readout from two ongoing studies to no later than mid-May 2026, tightening prior guidance that pointed more broadly to the first half of 2026. (investing.com)
2. Why a “timeline tighten” can still trigger selling
Even when a clinical update is directionally positive, biotech stocks can sell off if the market had already priced in the catalyst or if shares had rallied into the event. With ERAS recently trading near a 52-week high, a portion of today’s move appears consistent with profit-taking and de-risking ahead of the mid-May data release, when investors will get a clearer view of activity and tolerability for ERAS-0015. (investing.com)
3. What to watch next
The key near-term focus is the mid-May 2026 window for initial Phase 1 monotherapy results from ERAS-0015 trials (including AURORAS-1 and the China-based study run by its licensor). Investors will be watching for signs of clinical activity, safety/tolerability, and whether the readout supports expansion and combination plans, which could drive the next re-rating in either direction. (tradingview.com)